Symptoms and QOL with Ceritinib in ALK plus NSCLC Patients with/without Brain Metastases

被引：0
|
作者：
Crino, Lucio [1 ]
Ahn, Myung-Ju [2 ]
De Marinis, Filippo [3 ]
Groen, H. J. M. [4 ,5 ]
Wakelee, Heather A. [6 ]
Hida, Toyoaki [7 ]
Mok, Tony [8 ]
Shaw, Alice [9 ]
Felip, Enriqueta [10 ]
Nishio, Makoto [11 ]
Scagliotti, Giorgio V. V. [12 ]
Branle, Fabrice [13 ]
Emeremni, Chetachi [14 ]
Sutradhar, Santosh [15 ]
Quadrigli, Massimiliano [13 ]
Zhang, Jie [15 ]
Spigel, David [16 ]
机构：
[1] Perugia Hosp, Perugia, Italy
[2] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
[3] European Inst Oncol, Thorac Oncol Div, Milan, Italy
[4] Univ Groningen, Groningen, Netherlands
[5] Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands
[6] Stanford Univ, Dept Med, Div Oncol, Stanford, CA 94305 USA
[7] Aichi Canc Ctr, Dept Thorac Oncol, Nagoya, Aichi 464, Japan
[8] Chinese Univ Hong Kong, Shatin, Hong Kong, Peoples R China
[9] Massachusetts Gen Hosp, Boston, MA 02114 USA
[10] Vall DHebron Univ Hosp, Barcelona, Spain
[11] Japanese Fdn Canc Res, Tokyo, Japan
[12] Univ Turin, Turin, Italy
[13] Novartis Pharma AG, Basel, Switzerland
[14] Novartis Pharma AG, E Hanover, NJ USA
[15] Novartis Pharmaceut, E Hanover, NJ USA
[16] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 09期
关键词：
ALK Inhibitor; brain metastases; Patient-reported outcomes; Ceritinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MINI31.13
引用
收藏
页码：S379 / S379
页数：1
相关论文
共 50 条
  • [1] PROs with Ceritinib in ALKi-Naive ALK plus NSCLC Patients with and without Brain Metastases
    Park, Keunchil
    Felip, Enriqueta
    Orlov, Sergey
    Yu, Chong-Jen
    Tsai, Chun-Ming
    Nishio, Makoto
    Dols, Manuel Cobo
    Mckeage, Mark
    Su, Wu-Chou
    Mok, Tony
    Scagliotti, Giorgio V. V.
    Spigel, David R.
    Zhang, Jie
    Branle, Fabrice
    Emeremni, Chetachi
    Sutradhar, Santosh
    Quadrigli, Massimiliano
    Shaw, Alice
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S379 - S380
  • [2] Whole Body and Intracranial Efficacy of Ceritinib in ALK-inhibitor Naive Patients with ALK plus NSCLC and Brain Metastases: Results of ASCEND 1 and 3
    Shaw, Alice T.
    Spigel, David R.
    Tan, Daniel S. -W.
    Kim, Dong-Wan
    Mehra, Ranee
    Orlov, Sergey
    Park, Keunchil
    Yu, Chong-Jen
    Mok, Tony
    Nishio, Makoto
    Scagliotti, Giorgio
    Sutradhar, Santosh
    Cesic, Dajana
    Felip, Enriqueta
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : S256 - S256
  • [3] SYMPTOMATIC AND ECONOMIC BURDEN OF BRAIN METASTASES IN PATIENTS WITH ALK plus NSCLC
    Macalalad, Alexander
    Sasane, Medha
    Zhang, Jie
    Culver, Kenneth
    Dea, Katherine
    Nitulescu, Roy
    Wu, Eric
    Guerin, Annie
    NEURO-ONCOLOGY, 2014, 16
  • [4] Role of QoL in Treatment Decisions for Patients with ALK plus NSCLC
    Law, H.
    King, J. C.
    Lin, H. M.
    Curran, E.
    Wiens, J.
    Cruz, L.
    Blender, J.
    Venanzi, E. S.
    Schenk, E.
    Lin, J. J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S113 - S114
  • [5] Ceritinib in ALK plus NSCLC Metastatic to Brain and/or Leptomeninges: The ASCEND-7 Study
    Chow, Laura Q.
    Barlesi, Fabrice
    Bertino, Erin M.
    Kim, Dong-Wan
    Van Den Bent, Martin J.
    Wakelee, Heather A.
    Wen, Patrick Y.
    Arratia, Pilar Cazorla
    Shen, Junwu
    Branle, Fabrice
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S550 - S551
  • [6] Pre-treated Patients with ALK-positive NSCLC benefit from Zykadia® (Ceritinib) - also in Brain Metastases
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2015, 38 (12) : 712 - 712
  • [7] A Multicenter Phase 1B Study of Ceritinib plus Nivolumab in Patients with ALK plus NSCLC
    Shaw, Alice
    Loong, Herbert
    Tan, Daniel S. -W.
    Griscti, Kerry
    Gao, Haitao
    Finckenstein, Friedrich
    Scott, Jeffrey
    Vansteenkiste, Johan
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S430 - S430
  • [8] Experience from the ASCEND-1 trial: Ceritinib in patients (Pts) with ALK-rearranged (ALK plus ) Non-Small Cell Lung Cancer (NSCLC) and brain metastases
    Thomas, M.
    Schuler, M.
    Potzner, M.
    Szczudlo, T.
    Sutradhar, S.
    Yovine, A.
    Wolf, J.
    Oncology Research and Treatment, 2015, 38 : 270 - 270
  • [9] Outcome of Patients with ALK plus NSCLC and Brain Metastases in Relation to Disease Burden and Clinical Management
    De Petris, Luigi
    Friesland, Signe
    Brodin, Daniel
    Carstens, Hanna
    Falkenius, Johan
    Grundberg, Oscar
    Lofdahl, Magnus
    Helleday, Clara Lenneby
    Karimi, Reza
    Ojdahl-Boden, Anna
    Tsakonas, Georgios
    Ekman, Simon
    Kolbeck, Karl-Gustav
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S940 - S941
  • [10] Comparison of clinical and MRI features of brain metastases between ALK plus and ALK- NSCLC
    Ren, Xiaolu
    Zhang, Xuting
    Lei, Xiaoyan
    Ma, Weiqin
    Zhang, Ting
    Wang, Yuxiang
    Ren, Jiwei
    CANCER MEDICINE, 2024, 13 (11):
12345